V.Chandregowda, G.Chandrasekar
Abstract
Formamidine intermediates have been prepared by cost effective reagents and using these formamidines, prepared anticancer agents Gefitinib and Erlotinib, approved by US FDA for the treatment of non-small-cell-lung cancer and pancreatic cancer. This convergent process reports an improvement in the procedure, yields and reaction times.